ArticleFrontiers in psychiatry2026
Locomotor and endocrine alterations link to metabolic dysfunction induced by pathopharmacological interaction between neurodevelopmental disorders and antipsychotics: evidence from clinical and animal study.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Beyond the well-known metabolic side effects of second-generation antipsychotics (SGAs), recent studies suggest that neurodevelopmental disorders (NDDs) themselves confer an underlying susceptibility to metabolic dysregulation. However, it remains unclear whether a combined effect exists between SGAs and the NDD condition regarding metabolic syndrome, and which NDD-related pathophysiological changes contribute to metabolic disturbance. Methods: This study applies a translational framework combining retrospective clinical data from drug-naïve children with NDDs and a prenatal polyinosinic:polycytidylic acid (Poly I:C) rat model. Results: Baseline variations in lipid and glucose disturbances were observed in both cohorts, and these metabolic imbalances were further increased in adult female rats following long-term olanzapine or risperidone treatment, with significant interaction effect between Poly I:C and SGA observed for HOMA-IR. Moreover, the significant effects of both Poly I:C and SGAs on adipokines (leptin and adiponectin) and locomotor activity, with SGA-driven changes in insulin and prolactin, indicate that altered locomotion and divergent endocrine modulation serve as candidate pathways contributing to NDD-related metabolic risk. Discussion: These results highlight that NDD-related locomotor and endocrine changes should be considered as potential biological factors when finding effective strategies for preventing metabolic events during SGAs medication. These results underscore the clinical importance of metabolic monitoring in pediatric psychopharmacology, even prior to pharmacologic exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.